Literature DB >> 15241504

[Primary prevention of diabetes mellitus type 2].

B Gallwitz1.   

Abstract

The increasing incidence of type 2 diabetes constitutes a considerable individual and socio-economic risk, therefore preventive concepts are urgently needed. Three prospective studies show that a "life-style-intervention" as well as drugs can prevent the development of diabetes as well as cardiovascular complications: The Diabetes Prevention Study (DPS) evaluated the influence of a "life-style-intervention". The Diabetes Prevention Program (DPP) additionally examined the effect of metformin. In the STOP-NIDDM-Study acarbose was used for diabetes prevention and cardiovascular endpoints were also evaluated. The incidence of type 2 diabetes can be significantly reduced by a "life-style-intervention" and also by the administration of metformin or acarbose. With acarbose cardiovascular events are reduced significantly and comparably to a therapy with statins in primary prevention.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15241504     DOI: 10.1007/s00108-004-1214-7

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  23 in total

Review 1.  The prevention or delay of type 2 diabetes.

Authors: 
Journal:  Diabetes Care       Date:  2002-04       Impact factor: 19.112

2.  The Diabetes Prevention Program: baseline characteristics of the randomized cohort. The Diabetes Prevention Program Research Group.

Authors: 
Journal:  Diabetes Care       Date:  2000-11       Impact factor: 19.112

3.  High blood glucose concentration is a risk factor for mortality in middle-aged nondiabetic men. 20-year follow-up in the Whitehall Study, the Paris Prospective Study, and the Helsinki Policemen Study.

Authors:  B Balkau; M Shipley; R J Jarrett; K Pyörälä; M Pyörälä; A Forhan; E Eschwège
Journal:  Diabetes Care       Date:  1998-03       Impact factor: 19.112

4.  Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study.

Authors:  X R Pan; G W Li; Y H Hu; J X Wang; W Y Yang; Z X An; Z X Hu; J Lin; J Z Xiao; H B Cao; P A Liu; X G Jiang; Y Y Jiang; J P Wang; H Zheng; H Zhang; P H Bennett; B V Howard
Journal:  Diabetes Care       Date:  1997-04       Impact factor: 19.112

5.  Risk of diabetes in the new diagnostic category of impaired fasting glucose: a prospective analysis.

Authors:  O Vaccaro; G Ruffa; G Imperatore; V Iovino; A A Rivellese; G Riccardi
Journal:  Diabetes Care       Date:  1999-09       Impact factor: 19.112

6.  Post-challenge hyperglycaemia relates more strongly than fasting hyperglycaemia with carotid intima-media thickness: the RIAD Study. Risk Factors in Impaired Glucose Tolerance for Atherosclerosis and Diabetes.

Authors:  M Hanefeld; C Koehler; E Henkel; K Fuecker; F Schaper; T Temelkova-Kurktschiev
Journal:  Diabet Med       Date:  2000-12       Impact factor: 4.359

7.  Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial.

Authors:  Jean-Louis Chiasson; Robert G Josse; Ramon Gomis; Markolf Hanefeld; Avraham Karasik; Markku Laakso
Journal:  JAMA       Date:  2003-07-23       Impact factor: 56.272

8.  Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study.

Authors:  Anna Norhammar; Ake Tenerz; Göran Nilsson; Anders Hamsten; Suad Efendíc; Lars Rydén; Klas Malmberg
Journal:  Lancet       Date:  2002-06-22       Impact factor: 79.321

9.  [Influence of impaired glucose tolerance on long-term survival after acute myocardial infarction].

Authors:  J J Meier; S Deifuss; B Gallwitz; A Klamann; W Schmiegel; M A Nauck
Journal:  Dtsch Med Wochenschr       Date:  2002-05-24       Impact factor: 0.628

10.  Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial.

Authors:  Jean-Louis Chiasson; Robert G Josse; Ramon Gomis; Markolf Hanefeld; Avraham Karasik; Markku Laakso
Journal:  Lancet       Date:  2002-06-15       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.